RECIST and iRECIST criteria for the evaluation of nivolumab + ipilimumab in MSI/dMMR mCRC

Response Evaluation Criteria in Solid Tumors (RECIST)Подробнее

Nivolumab/Ipilimumab Combination Data Promising in MSI-H/dMMR mCRCПодробнее

Remaining questions for the treatment of patients with MSI/dMMR mCRC with immunotherapyПодробнее

iRECIST and Immunotherapy Application in the follow up of patientsПодробнее

How accurate is RECIST 1.1 for assessing tumor response?Подробнее

Imaging 101: Immunotherapy CriteriaПодробнее

CheckMate 8HW: HRQoL outcomes of nivolumab and ipilimumab in MSI-H/dMMR mCRCПодробнее

CheckMate 8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRCПодробнее

HRQoL findings from CheckMate 8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRCПодробнее

Promising CheckMate-142 Data for Second-Line Ipilimumab Plus Nivolumab in mCRCПодробнее

Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with res...Подробнее

Nivolumab and Ipilimumab Combination in Frontline mCRCПодробнее

RECISTПодробнее

Webinar: The evolution of Response Evaluation Criteria in Cancer ImmunotherapyПодробнее

Treatment with anti-PD-1 inhibitor in metastatic NSCLC past RECIST progression may not be beneficialПодробнее

Response Evaluation Criteria In Solid Tumors (Recorded live)Подробнее

Dr. Overman on Nivolumab and Ipilimumab in Patients With MSI-H CRCПодробнее

Long-term results from CheckMate 040: nivolumab + ipilimumab in advanced HCCПодробнее

New Long-term Data 'Clearly Favor' Combination Ipilimumab/Nivolumab in MelanomaПодробнее